What question did this study set out to answer?

This study compares the efficacy and toxicity of two doses of melphalan as a conditioning regimen prior to autologous stem cell transplantation in multiple myeloma patients.

December 8, 2025BloodOpen Access

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

View Full Paper

Ask AI

Bookmark

Authors

BCBeatriz Chiclana-Rodríguez JRJuan Luis Reguera ECEusebio Martín Chacón

Discussion

Member takes

Overview

Compared melphalan doses of 140 mg/m² and 200 mg/m² in multiple myeloma patients, showing no significant differences in toxicity and efficacy.

Key Points

This study compares the efficacy and toxicity of two doses of melphalan as a conditioning regimen prior to autologous stem cell transplantation in multiple myeloma patients.
Retrospective observational single-center study
282 multiple myeloma patients undergoing autologous stem cell transplantation
Comparative analysis of 140 mg/m² vs 200 mg/m² melphalan
No significant differences in toxicity parameters observed between Mel140 and Mel200 groups
Complete remission rates were similar, with Mel140 at 60.9% and Mel200 at 67.1% at three months
Overall survival rates were 85.1% for Mel140 and 89.7% for Mel200 after a median follow-up of 26 months

Cite This Study

Chiclana-Rodríguez et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da92 https://doi.org/10.1182/blood-2025-4061

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

View Full Paper

Ask AI

Bookmark

Authors

BCBeatriz Chiclana-Rodríguez JRJuan Luis Reguera ECEusebio Martín Chacón

Discussion

Member takes

Overview

Compared melphalan doses of 140 mg/m² and 200 mg/m² in multiple myeloma patients, showing no significant differences in toxicity and efficacy.

Key Points

This study compares the efficacy and toxicity of two doses of melphalan as a conditioning regimen prior to autologous stem cell transplantation in multiple myeloma patients.
Retrospective observational single-center study
282 multiple myeloma patients undergoing autologous stem cell transplantation
Comparative analysis of 140 mg/m² vs 200 mg/m² melphalan
No significant differences in toxicity parameters observed between Mel140 and Mel200 groups
Complete remission rates were similar, with Mel140 at 60.9% and Mel200 at 67.1% at three months
Overall survival rates were 85.1% for Mel140 and 89.7% for Mel200 after a median follow-up of 26 months

Cite This Study

Chiclana-Rodríguez et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da92 https://doi.org/10.1182/blood-2025-4061

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark